$AIB — A Small-Cap AI Data Center Play With a $1.32B Nebius Contract

Disclaimer: yes, I ran this through AI to clean it up. Trust me you’d complain a lot more if you had to read my original shit sentences..

I’ve been digging through the smaller AI/data-center names, and AIB is one that still looks unusually cheap to me relative to what has changed over the last few weeks.

At around $1.39/share, AIB is valued at roughly $105M.

At June 30, the company reported $52.8M in cash.

Since then, AIB has signed Nebius for 50 MW of critical IT capacity under a 12-year agreement that AIB values at approximately $1.32B over the initial term.

So you have a company with roughly a $105M equity value, a last-reported cash balance equal to about half of that, and a signed AI data-center contract worth more than 12x the current market cap.

That obviously does not mean AIB is worth $1.32B. The project still needs to be financed, built and operated.

But I think the valuation setup is hard to ignore.

The Nebius deal changes AIB quite a bit

Before Nebius, AIB was mostly a power-and-development story.

They had sites, utility capacity and plans to attract AI/HPC customers, but there was still a big question:

Could they actually land a serious tenant?

Now they have 50 MW contracted to Nebius for an initial 12-year term, with two additional five-year renewal options.

The basic AIB model now looks pretty simple:

Secure power → sign AI/HPC customer → finance project → build capacity → collect long-term contracted revenue

CLT1 is the first real test of whether that model works.

The customer side has already been substantially de-risked.

The power position is probably the most important asset

Anyone following the AI infrastructure buildout knows how difficult it has become to secure meaningful amounts of power on useful timelines.

At CLT1, AIB has 65 MW of contracted utility power.

Fifty MW of that is now committed to Nebius.

AIB also acquired a Texas site with 15 MW of existing primary electric service plus up to another 40 MW under a utility facilities agreement.

That gives AIB roughly:

65 MW at CLT1

plus

55 MW at Texas

or about 120 MW of existing/contracted utility capacity across the two sites.

I would not value all 120 MW equally.

The 50 MW tied to Nebius is clearly worth more today because there is already a customer attached.

But the Texas site gives AIB another meaningful block of power to market.

If they sign another credible AI/HPC tenant there, I think that becomes a very important catalyst.

The financing structure may be just as important as the contract

The obvious question is how a company this small builds a project this large.

AIB says the Nebius agreement includes significant customer funding support, including contractual prepayments expected to fund a meaningful portion of CLT1’s initial development.

Management has also said that, based on the current development plan, AIB does not currently anticipate requiring corporate-level common equity to fund CLT1.

That statement matters a lot to me.

It does not mean dilution is impossible.

It does not mean all of the financing risk is gone.

But there is a huge difference between:

raising hundreds of millions through common stock

and

using customer prepayments plus project-level financing backed by a 12-year contract.

If AIB can build CLT1 without heavily diluting existing shareholders, I think the current valuation becomes much harder to justify.

The timeline is not that far away

AIB plans to deliver CLT1 in phases.

The first data hall is expected to provide approximately 25 MW of critical IT capacity, followed by another 25 MW in the second phase.

That matters because AIB does not have to wait for the entire 50 MW project to be finished before the story starts changing.

The next major step is simply proving they can move from:

signed contract

to

financed construction

to

operating capacity

If they deliver that first 25 MW, the company becomes a very different business than the one the market was valuing before the Nebius deal.

The balance sheet gives them some breathing room

At June 30, AIB reported roughly $52.8M in cash, $90.4M in total assets, $7.7M in total liabilities and $82.7M in shareholders’ equity.

The $52.8M cash figure is obviously not the exact cash balance today. AIB has used cash since then, including for the Texas acquisition.

Still, relative to a roughly $105M market cap, it is a meaningful starting position.

AIB also disclosed 75,979,466 common shares outstanding.

Including warrants, equity-plan shares and potential earnout shares, the company showed an illustrative fully diluted count of roughly 88.9M shares.

So dilution is something I would absolutely keep an eye on.

But even on a fully diluted basis, the valuation still looks small relative to the opportunity if CLT1 gets built successfully.

Texas may be the next important piece

AIB paid approximately $17.225M for the Texas acquisition.

The site has 15 MW of existing utility service plus up to another 40 MW under the facilities agreement.

So potentially 55 MW.

Right now, Texas does not have an announced Nebius-type tenant.

That is why I would not give those MW the same value as the contracted CLT1 capacity.

But if AIB signs another serious customer against Texas, the thesis gets a lot more interesting.

At that point Nebius no longer looks like a one-off deal.

It starts to look like AIB may have a repeatable model for converting secured power into long-term AI infrastructure contracts.

The risks

This is still a small-cap infrastructure company trying to execute a very large project.

The main risks I see are:

  • Construction delays
  • Cost overruns
  • Project financing risk
  • Future dilution
  • Heavy reliance on Nebius
  • Failure to deliver CLT1 on schedule
  • Giving too much value to development-stage power before customers are signed

So this is definitely not a low-risk stock.

The next year should tell us a lot.

Why I think AIB is interesting

The market still seems to be valuing AIB much closer to the company it was before Nebius.

But the company now has:

50 MW contracted to Nebius

12-year initial term

two additional five-year renewal options

$1.32B of disclosed initial contract value

65 MW of contracted utility power at CLT1

another potential 55 MW at the Texas site

and a $52.8M last-reported cash balance.

Most importantly, management says corporate-level common equity is not currently expected to be required to fund CLT1.

For me, the thesis comes down to three things:

1. Finance CLT1 without crushing shareholders

2. Deliver the first 25 MW to Nebius

3. Sign another credible tenant against the remaining power portfolio

If they can do those three things, I think AIB gets valued very differently than it is today.

They do not have to become the next CoreWeave.

They just have to prove the model works.

Disclosure: I own shares of AIB.

Not financial advice. Small-cap infrastructure stocks carry significant execution, financing and dilution risk.

reddit.com
u/SecondPrevious7385 — 5 days ago
▲ 81 r/biotech_stocks+1 crossposts

$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne

I have been searching for small oncology companies with the potential to experience the kind of revaluation that occurs when convincing clinical data finally attracts market attention. MAIA Biotechnology ($MAIA) may be one of the more interesting examples I have found.

MAIA currently trades around $1.33, giving it a market capitalization of approximately $80 million with 60.8 million shares outstanding. This remains a tiny valuation for a company that already has a randomized Phase 3 cancer trial underway. (Current market data)

The entire thesis revolves around ateganosine, previously called THIO, a potentially first-in-class small molecule designed to attack cancer through telomeres while simultaneously activating an immune response.

What does ateganosine actually do?

Telomeres protect the ends of chromosomes and help cancer cells continue dividing. Ateganosine is designed to be incorporated into the telomeres of telomerase-positive cancer cells, damaging those telomeres and causing cancer-cell death.

The damaged telomeric material may also activate the cGAS/STING immune pathway and stimulate adaptive immune responses. In theory, this can turn a tumor that has stopped responding to checkpoint inhibitors back into one the immune system can recognize and attack.

This mechanism is supported by peer-reviewed research. A 2020 Cancer Cell study found that 6-thio-dG produced telomere-associated DNA damage, activated STING-dependent antitumor immunity and improved responses to checkpoint inhibition in preclinical models. (Cancer Cell study)

A separate 2015 study found that 6-thio-dG produced rapid death in telomerase-positive cancer cells while having considerably less effect on normal telomerase-negative cells. (AACR study)

The goal is therefore bigger than simply adding another chemotherapy. MAIA is attempting to create an entirely new class of telomere-targeting immunotherapy that could potentially be combined with several existing checkpoint inhibitors.

The Phase 2 results are difficult to ignore

MAIA’s THIO-101 Phase 2 study enrolled heavily pretreated patients with advanced non-small cell lung cancer, or NSCLC, whose cancers had already progressed after checkpoint inhibitors and chemotherapy.

In Parts A and B, 22 third-line patients who received at least one dose produced an estimated median overall survival of:

  • 17.8 months
  • 95% confidence-interval lower bound of 12.5 months
  • 99% confidence-interval lower bound of 10.8 months

Published studies cited by MAIA indicate approximately five to six months of median survival for chemotherapy in comparable third-line patients. That makes the observed 17.8 months close to three times the historical benchmark. (Phase 2 survival update)

Eight patients from Parts A and B survived beyond two years without receiving another subsequent line of therapy, and one third-line patient had survived more than 33 months as of June 2026. (Long-term survival update)

Earlier results at the selected 180 mg dose also showed:

  • 38% objective response rate
  • 85% disease-control rate
  • 5.5 months median progression-free survival
  • 78% survival at six months

The important qualification is that the 38% response rate came from only eight evaluable patients at the selected dose. These are encouraging results, but the sample was small and the comparisons were against historical chemotherapy data rather than a randomized control arm. (ASCO 2024 results)

MAIA has subsequently expanded the Phase 2 trial. Initial Part C results reported in July 2026 showed disease control in 19 of 21 evaluable patients, equal to a 90.5% disease-control rate. Every patient in this group had previously received docetaxel and had demonstrated resistance to immunotherapy and other chemotherapy. (Part C expansion results)

That does not prove the drug works. It does show that the original signal has continued appearing as additional patients have been treated.

The real test is now underway

MAIA began its randomized Phase 3 THIO-104 trial in December 2025.

The trial will enroll up to 300 patients with advanced third-line NSCLC and randomize them 1:1 between:

  • Ateganosine followed by Regeneron’s checkpoint inhibitor Libtayo
  • Investigator-selected chemotherapy using docetaxel, gemcitabine or vinorelbine

The primary endpoint is overall survival, with response rate, progression-free survival and duration of response included as secondary endpoints. (THIO-104 Phase 3 design)

As of June 2026, 29 patients had been dosed across 34 active sites in six countries. Management was targeting up to 100 enrolled patients by the end of 2026 and expects sufficient survival data for an interim analysis in 2027. (Phase 3 enrollment update)

This randomized trial is the key. If ateganosine produces anything close to the 17.8-month Phase 2 survival result against a concurrent chemotherapy control, an $80 million valuation would be difficult to reconcile with the drug’s commercial potential.

The FDA has already granted ateganosine Fast Track designation for third-line NSCLC. Fast Track allows more frequent FDA interaction and can potentially support rolling review or priority review, although it does not guarantee approval. (FDA Fast Track announcement)

This is a very large market

Lung cancer remains the leading cause of cancer death worldwide, with approximately 2.5 million new cases and 1.8 million deaths in 2022. (World Health Organization)

Approximately 80% to 85% of lung cancers are NSCLC. (American Cancer Society)

Third-line NSCLC is only part of this total market, so it would be misleading to treat the entire NSCLC market as MAIA’s immediately addressable opportunity. However, the broader commercial market is enormous. Grand View Research estimates that the worldwide NSCLC therapeutics market will grow from approximately $27.1 billion in 2026 to $63.5 billion by 2033. (NSCLC market research)

More significantly, there remains no universally accepted third-line standard after patients have failed both chemotherapy and checkpoint inhibition. (Peer-reviewed review of third-line NSCLC)

Even a modest share of this treatment population could support annual revenue many times MAIA’s present market capitalization. Success in NSCLC could also validate the platform for other telomerase-positive cancers.

The large-pharma relationships are real

MAIA has clinical-supply relationships with three major oncology companies:

Regeneron

Regeneron supplies Libtayo, or cemiplimab, for THIO-101. The agreement was expanded in December 2024 to cover the Phase 2 expansion. MAIA sponsors the study and retains its worldwide commercial rights to ateganosine. (Regeneron agreement)

BeOne Medicines, formerly BeiGene

BeOne agreed to supply tislelizumab for planned studies combining it with ateganosine in hepatocellular carcinoma, small-cell lung cancer and colorectal cancer. (BeOne agreement)

Roche

MAIA entered a master clinical-supply agreement with Roche covering future studies of ateganosine followed by Roche’s checkpoint inhibitor Tecentriq, or atezolizumab, in difficult-to-treat cancers. (Roche agreement)

These are supply collaborations, not licensing transactions or buyout agreements. MAIA still pays for its clinical trials. However, having Regeneron, Roche and BeOne provide their checkpoint inhibitors reduces trial costs and allows ateganosine to be tested with several commercially established immunotherapies.

It also preserves strategic flexibility because MAIA controls the worldwide development and commercialization rights to ateganosine.

Insiders are putting in their own money

The insider buying is one of the more interesting parts of this story.

In November 2025, CEO Vlad Vitoc and directors Cristian Luput and Stan Smith purchased approximately 182,445 shares in open-market transactions at an average price of approximately $1.06. Vitoc personally purchased 94,300 shares at an average of $1.08. (November insider purchases)

In June 2026:

  • CEO Vlad Vitoc purchased another 72,700 shares at an average of approximately $1.39, spending roughly $101,000.
  • Director Stan Smith purchased 75,000 shares at approximately $1.34, spending roughly $100,000.

(June insider purchases)

That represents approximately 330,000 open-market shares and nearly $400,000 invested by leadership across those two disclosed rounds.

MAIA’s 2026 proxy also reported that Vitoc beneficially owned approximately 4.14 million shares and exercisable securities, equal to 6.5% of the company at that time. (2026 proxy statement)

Insider buying cannot validate a clinical trial, but repeated open-market purchases are more meaningful than executives simply receiving stock options as compensation.

The CEO has relevant oncology experience

Founder and CEO Dr. Vlad Vitoc is a physician with an MBA and more than 25 years of pharmaceutical and biotechnology experience.

Before MAIA, he held leadership roles at Bayer, Astellas, Cephalon and Incyte. His experience includes the development or commercialization of major oncology drugs, and MAIA’s broader leadership team has worked on drugs including Tarceva, Nexavar, Xtandi, Treanda and Zometa. (MAIA 2025 annual report)

Vitoc’s stated vision is to establish telomere targeting as a new cancer-treatment platform rather than develop ateganosine for only one narrow indication. MAIA is initially pursuing third-line NSCLC because the unmet need is high and the regulatory path is relatively clear, but the company is also exploring liver cancer, small-cell lung cancer, colorectal cancer and pediatric brain cancer.

The National Cancer Institute awarded MAIA a $2.3 million grant supporting the U.S. expansion of THIO-101, providing another external scientific review of the program. (NCI grant announcement)

Balance sheet and valuation

MAIA reported:

  • $27.6 million in cash at June 30, 2026
  • Approximately $12.1 million of operating cash burn during the first six months of 2026
  • 60.8 million shares outstanding
  • No product revenue

The company raised approximately $33 million gross in March 2026 by selling 22 million shares at $1.50. Management says those proceeds are expected to fully fund the ongoing Phase 3 trial. (MAIA Q2 2026 SEC filing)

The financing substantially improved MAIA’s balance sheet, but it also increased the outstanding share count from 38.6 million at the end of 2025 to 60.8 million by June 2026. That dilution is real and needs to be included in any valuation.

At approximately $80 million, the market is assigning only about $52 million of value above MAIA’s June cash balance to the clinical program, management team, intellectual property and pharma collaborations.

What could go wrong?

This remains an extremely speculative biotechnology investment.

The biggest risks are:

  1. The strongest survival data comes from only 22 third-line patients.
  2. THIO-101 was not randomized, so comparisons with historical chemotherapy results can be distorted by differences in patient selection.
  3. The earlier 38% response rate came from only eight evaluable patients at the selected dose.
  4. The randomized Phase 3 results may fail to reproduce the Phase 2 signal.
  5. MAIA has no commercial products or revenue and may eventually require additional capital.
  6. There are approximately 13.1 million outstanding warrants and 16.7 million stock options, creating potential future dilution.
  7. The Regeneron, Roche and BeOne relationships are supply agreements, not commitments to acquire or license ateganosine.
  8. A recently filed $150 million shelf registration creates additional financing flexibility but also a potential dilution overhang.

My thesis

I do not think MAIA currently has the most proven data in small-cap oncology. Its Phase 2 study was too small and lacked a randomized control.

What MAIA may have is one of the more asymmetric setups:

  • Approximately $80 million market cap
  • A first-in-class mechanism supported by published science
  • 17.8-month median survival in a population historically surviving approximately five to six months
  • 90.5% disease control in the initial Phase 2 expansion cohort
  • A randomized, 300-patient Phase 3 trial already underway
  • FDA Fast Track designation
  • Clinical-supply relationships with Regeneron, Roche and BeOne
  • Repeated open-market purchases by the CEO and directors
  • Cash that management expects will fund the Phase 3 trial
  • Interim Phase 3 data anticipated in 2027

The Phase 3 trial will determine whether this is a breakthrough or simply another encouraging small, single-arm oncology study that fails when tested against a proper control.

If Phase 3 survival lands anywhere near the Phase 2 result, I believe the company would be worth many multiples of its current valuation and would become an obvious licensing or acquisition candidate. If the survival advantage disappears in the randomized trial, the downside could be severe because nearly the entire valuation depends on ateganosine.

That is the bet: an approximately $80 million company attempting to prove that it can nearly triple survival in one of the most difficult areas of lung cancer treatment.

u/SecondPrevious7385 — 1 month ago

ZONE — am I missing something here? $800M Cerebras contract, $100M raise, and almost nobody discussing it

I've been digging into CleanCore Solutions ($ZONE) and I'm surprised there isn't more discussion about this company given how dramatically the story has changed over the last couple months.

This used to essentially be an aqueous ozone/cleaning company. In June, management announced a pivot into AI critical infrastructure/data centers.

Since then:

  • ZONE formed a JV with HST Technologies to develop AI/HPC data centers.
  • Its first announced project is a 200 MW West Texas campus, with potential expansion beyond that.
  • ZONE says its development pipeline is now 500+ MW.
  • More importantly, it signed a 10-year colocation agreement with Cerebras ($CBRS) for a Minnesota data center.
  • The Minnesota project is expected to have approximately 55 MW of utility capacity / 40 MW critical IT load.
  • Cerebras is taking 100% of the capacity.
  • ZONE says the initial 10-year contract represents approximately $800M in contract value, with two additional 10-year renewal options that could bring total potential contract value above $3B.
  • Initial revenue is expected in Q1 2027.

So this isn't simply a "we bought some land and someday AI companies might want it" story. They actually have a long-term colocation agreement with Cerebras.

But here's the ugly part: dilution.

ZONE just completed a $100M public offering at $0.25, consisting of 400M shares/pre-funded warrants plus warrants for another 400M shares.

That's enormous dilution and obviously changes how the company needs to be valued. On the other hand, the raise potentially provides the capital needed to actually build the Minnesota project rather than leaving this as another speculative data-center announcement.

Interestingly, CEO Tyler Hassen participated in the offering and acquired 2M shares at $0.25 plus accompanying warrants.

Management also just announced plans to change the corporate name from CleanCore Solutions to Zone Frontier, which makes considerably more sense given that this is effectively becoming an AI infrastructure company.

I'm not suggesting the old share price means anything after this financing. It doesn't. The fully diluted share count and capital requirements matter enormously here.

What I'm trying to understand is whether the market has gone too far in the opposite direction.

You now have a tiny public company attempting to transition into an AI infrastructure developer with:

500+ MW development pipeline
200 MW Texas project
40 MW critical IT Minnesota project
100% pre-leased to Cerebras
~$800M initial contracted value
~$100M newly raised capital

Obviously there are major risks: dilution, execution, construction financing, customer concentration, enormous capex requirements, and the fact that this company has almost no historical track record operating data centers.

But that's also why I find it interesting.

At what valuation does the Cerebras contract + development pipeline outweigh the dilution/execution risk?

I'm genuinely interested in the bear case here. What am I missing?

Sources: ZONE SEC filings / July 29 Cerebras announcement / August 12 financing announcement.

reddit.com
u/SecondPrevious7385 — 2 months ago
▲ 161 r/liftedtrucks+4 crossposts

Looking at lifting a 1972 GMC C15 (2WD) – anyone running a lifted coil-spring/trailing-arm truck?

I'm looking at lifting my 1972 GMC C15 2WD a few inches. It has the factory coil-spring trailing-arm rear suspension and independent front suspension.

I'm thinking around a 4" suspension lift with 35x12.50R15s on 15x8 Mickey Thompson Classic III wheels.

I've found lots of information on lifted K10/K15s, but there doesn't seem to be much out there for the coil-spring C15s.

I'd love to see any pictures of your lifted C10/C15s and hear what suspension setup you went with. Any advice or things you'd do differently would be greatly appreciated.

I know... this probably goes against the cardinal rule... 4x4s go up, 2WDs go down.

Thanks!!!

u/SecondPrevious7385 — 4 months ago